-
Selpercatinib, sold
under the
brand name
Retevmo among others, is a
targeted medication for the
treatment of
cancers in
people whose tumors have an alteration...
-
selective RET inhibitors.
Around 2017, the
first selective RET
inhibitors selpercatinib (LOXO-292) and
pralsetinib (BLU-667)
started their first phase I/II...
- as an
inhibitor of SRC kinase.
Pralsetinib Rebecsinib Resigratinib Selpercatinib Zeteletinib Repetto M,
Crimini E,
Ascione L,
Boscolo Bielo L, Belli...
-
early stage human clinical trials.
Enbezotinib Pralsetinib Rebecsinib Selpercatinib Zeteletinib Franovic A,
Mohan A, Uryu S, Wu Q,
Jiang P,
Miller N, et al...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
-
potential treatment for leukemia.
Enbezotinib Pralsetinib Resigratinib Selpercatinib Zeteletinib Butler MS (September 2013). "Remediating
cancer via splicing...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
